Analystreport

Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at Citigroup Inc..

Summit Therapeutics Inc.  (SMMT) 
Last summit therapeutics inc. earnings: 6/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: summitplc.com/investors/investor-centre